Zhaoke Ophthalmology Partners with TSH Biopharm to Commercialize BRIMOCHOL PF in Taiwan
I'm PortAI, I can summarize articles.
Zhaoke Ophthalmology Limited has partnered with TSH Biopharm to commercialize BRIMOCHOL™ PF in Taiwan. TSH Biopharm gains exclusive rights to register, import, promote, distribute, market, and sell the product. BRIMOCHOL™ PF has completed Phase 3 trials and has a PDUFA date of January 28, 2026. The announcement was made via the Hong Kong Stock Exchange on December 08, 2025.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments